Expression of the Transmembrane Glycoprotein CD44s Is Potentially an Independent Predictor of Recurrence in Hepatocellular Carcinoma.
- Author:
Han Suk RYU
1
;
Sun Hoo PARK
;
Kyung Bun LEE
;
Eun SHIN
;
Ja June JANG
Author Information
1. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea. tripj@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Hepatocellular carcinoma;
CD44s antigen;
Protein microarrays
- MeSH:
Animals;
Antigens, CD44;
Carcinoma, Hepatocellular;
Disease-Free Survival;
Glycoproteins;
Humans;
Mice;
Multivariate Analysis;
Neoplasm Metastasis;
Protein Array Analysis;
Recurrence
- From:Gut and Liver
2011;5(2):204-209
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Cluster differentiation 44 standard isoform (CD44s) is a transmembrane glycoprotein. CD44s is a known prognostic factor in various cancers, due to its involvement in tumor cell growth, invasion and metastasis. Its prognostic role, however, is debated because it can be a positive or negative prognostic factor depending on tumor type and is still an ambiguous prognostic indicator in other cancers, especially hepatocellular carcinoma (HCC). We investigated the relationship between CD44s expression and survival in HCC patients. METHODS: A total of 260 HCC samples were collected to generate a tissue microarray. Staining of the arrays with a primary mouse CD44s monoclonal antibody was followed by evaluation of the relationship between CD44s expression and tumor differentiation. The effect of CD44s expression on patient survival was analyzed. RESULTS: CD44s protein expression correlated with histological grade (most and worst Edmondson grade) of the HCC (p=0.029 and p=0.039, respectively) and adversely affected the disease free survival period based on univariate and multivariate analyses (p=0.038 and p=0.077, respectively). CONCLUSIONS: High CD44s protein expression correlates with shorter disease free survival and poorly differentiated HCC. CD44s-targeted therapy may be efficacious for HCC treatment in the future.
